STOCKWATCH
·
Pharmaceuticals
ESG16 Dec 2025, 10:05 am

Lupin Secures SBTi Validation for Emission Reduction Targets

AI Summary

Global pharma major Lupin Limited announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes — Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5°C. This milestone underscores Lupin’s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.

Key Highlights

  • Lupin’s GHG emissions reduction targets validated by the Science Based Targets initiative (SBTi).
  • Validation covers all three emission scopes - Scope 1, Scope 2, and Scope 3.
  • Targets align with the Paris Agreement to limit global temperature rise to 1.5°C.
  • Lupin is among a select group that has achieved comprehensive SBTi validation within a year.
  • Validation underscores Lupin’s commitment to sustainability and decisive climate action.
LUPIN
Pharmaceuticals
LUPIN LTD.

Price Impact